These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23394882)

  • 1. Does suspicion of prostate cancer on integrated T2 and diffusion-weighted MRI predict more adverse pathology on radical prostatectomy?
    Borofsky MS; Rosenkrantz AB; Abraham N; Jain R; Taneja SS
    Urology; 2013 Jun; 81(6):1279-83. PubMed ID: 23394882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
    Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
    AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of preoperative 3.0-Tesla magnetic resonance imaging to predict the absence of side-specific extracapsular extension of prostate cancer.
    Hara T; Nakanishi H; Nakagawa T; Komiyama M; Kawahara T; Manabe T; Miyake M; Arai E; Kanai Y; Fujimoto H
    Int J Urol; 2013 Oct; 20(10):993-9. PubMed ID: 23360237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging.
    Song SH; Pak S; Park S; Song C; Jeong IG; Choi HJ; Kim JK; Cho KS; Kim CS; Ahn H
    J Urol; 2014 Aug; 192(2):402-8. PubMed ID: 24631106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging.
    Nishida S; Kinoshita H; Mishima T; Kurokawa H; Sakaida N; Matsuda T
    Int J Urol; 2011 Sep; 18(9):653-8. PubMed ID: 21790792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of diffusion-weighted imaging at 3 T for prediction of extracapsular extension in patients with prostate cancer: a preliminary study.
    Chong Y; Kim CK; Park SY; Park BK; Kwon GY; Park JJ
    AJR Am J Roentgenol; 2014 Apr; 202(4):772-7. PubMed ID: 24660705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging.
    Woo S; Cho JY; Kim SY; Kim SH
    AJR Am J Roentgenol; 2015 Feb; 204(2):W168-75. PubMed ID: 25615777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance.
    Guzzo TJ; Resnick MJ; Canter DJ; Bivalacqua TJ; Rosen MA; Bergey MR; Magerfleisch L; Tomazewski JE; Wein AJ; Malkowicz SB
    Urol Oncol; 2012; 30(3):301-5. PubMed ID: 21856187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.
    Gondo T; Hricak H; Sala E; Zheng J; Moskowitz CS; Bernstein M; Eastham JA; Vargas HA
    Eur Radiol; 2014 Dec; 24(12):3161-70. PubMed ID: 25100337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
    Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series.
    Somford DM; Hambrock T; Hulsbergen-van de Kaa CA; Fütterer JJ; van Oort IM; van Basten JP; Karthaus HF; Witjes JA; Barentsz JO
    Invest Radiol; 2012 Mar; 47(3):153-8. PubMed ID: 22293513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of diffusional kurtosis imaging as a marker of adverse pathologic outcomes among prostate cancer active surveillance candidates undergoing radical prostatectomy.
    Rosenkrantz AB; Prabhu V; Sigmund EE; Babb JS; Deng FM; Taneja SS
    AJR Am J Roentgenol; 2013 Oct; 201(4):840-6. PubMed ID: 24059373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.